The Addition Of Bortezomib (Velcade®) To The Combination Of Mitoxantrone and Etoposide For Relapsed Or Refractory Acute Leukemia Does Not Appear To Improve The Likelihood Of Response: Results Of a Phase II Trial
Publication/Presentation Date
11-2013
Volume
122
Issue
21
First Page
2698
Last Page
2689
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS